欧盟批准-话题@MedSci

#欧盟批准#

135篇内容 | 2702人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1590029, encodeId=ed22159002995, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=欧盟批准Gilead的remdesivir，治疗新冠病毒COVID-19感染, objectType=article, longId=197033, objectId=67e319e03325, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67e319e03325, replyNumber=0, likeNumber=86, createdTime=2020-07-05, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67e319e03325, moduleTitle=欧盟批准Gilead的remdesivir，治疗新冠病毒COVID-19感染, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=67e319e03325)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590028, encodeId=12a91590028b9, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=欧盟批准强生的埃博拉病毒疫苗方案, objectType=article, longId=196916, objectId=7b3f196916dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b3f196916dd, replyNumber=0, likeNumber=79, createdTime=2020-07-03, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b3f196916dd, moduleTitle=欧盟批准强生的埃博拉病毒疫苗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b3f196916dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590027, encodeId=5679159002e2c, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=欧盟批准红细胞成熟剂Reblozyl，治疗输血依赖性贫血, objectType=article, longId=196866, objectId=ef0319686621, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef0319686621, replyNumber=0, likeNumber=72, createdTime=2020-07-02, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef0319686621, moduleTitle=欧盟批准红细胞成熟剂Reblozyl，治疗输血依赖性贫血, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef0319686621)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590026, encodeId=50e215900267b, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=欧盟批准维多珠单抗Entyvio上市，用作活动性溃疡性结肠炎或克罗恩病的维持治疗, objectType=article, longId=193811, objectId=4fa8193811f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4fa8193811f2, replyNumber=0, likeNumber=78, createdTime=2020-05-10, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4fa8193811f2, moduleTitle=欧盟批准维多珠单抗Entyvio上市，用作活动性溃疡性结肠炎或克罗恩病的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4fa8193811f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590025, encodeId=c65d1590025d9, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=欧盟批准诺华的IL-17单抗Cosentyx，用于治疗非放射线轴性脊柱关节炎, objectType=article, longId=193367, objectId=384819336e00, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=384819336e00, replyNumber=0, likeNumber=104, createdTime=2020-05-03, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=384819336e00, moduleTitle=欧盟批准诺华的IL-17单抗Cosentyx，用于治疗非放射线轴性脊柱关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=384819336e00)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590024, encodeId=1cb015900243c, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=欧盟批准Shionogi的新型抗生素Fetcroja——用于WHO指定的所有重点革兰氏阴性病原体, objectType=article, longId=193318, objectId=de90193318ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de90193318ff, replyNumber=0, likeNumber=73, createdTime=2020-05-03, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de90193318ff, moduleTitle=欧盟批准Shionogi的新型抗生素Fetcroja——用于WHO指定的所有重点革兰氏阴性病原体, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de90193318ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590023, encodeId=a55515900235b, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=欧盟批准武田的TKI抑制剂ALUNBRIG，用作ALK阳性非小细胞肺癌患者的一线治疗药物, objectType=article, longId=191689, objectId=a505191689b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a505191689b3, replyNumber=0, likeNumber=57, createdTime=2020-04-09, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a505191689b3, moduleTitle=欧盟批准武田的TKI抑制剂ALUNBRIG，用作ALK阳性非小细胞肺癌患者的一线治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a505191689b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590022, encodeId=1c9f1590022c2, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=欧盟批准2型糖尿病药物GLP-1受体激动剂Rybelsus, objectType=article, longId=191603, objectId=16ab191603bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16ab191603bc, replyNumber=0, likeNumber=76, createdTime=2020-04-08, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16ab191603bc, moduleTitle=欧盟批准2型糖尿病药物GLP-1受体激动剂Rybelsus, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16ab191603bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590021, encodeId=058915900210e, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=辉瑞的美罗华（利妥昔单抗）仿制药Ruxience，获得欧盟批准, objectType=article, longId=191492, objectId=9a9c19149256, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a9c19149256, replyNumber=0, likeNumber=124, createdTime=2020-04-06, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a9c19149256, moduleTitle=辉瑞的美罗华（利妥昔单抗）仿制药Ruxience，获得欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a9c19149256)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590020, encodeId=79f415900205b, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=Alnylam的第二款RNAi药物Givlaari，获得欧盟批准治疗肝卟啉症, objectType=article, longId=189441, objectId=02d9189441ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02d9189441ee, replyNumber=0, likeNumber=68, createdTime=2020-03-07, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02d9189441ee, moduleTitle=Alnylam的第二款RNAi药物Givlaari，获得欧盟批准治疗肝卟啉症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02d9189441ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590019, encodeId=d4501590019b6, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=诺华的抗血管内皮生长因子（VEGF）单抗Beovu获欧盟批准，用于治疗年龄相关的湿性黄斑变性, objectType=article, longId=188479, objectId=2f351884e941, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f351884e941, replyNumber=0, likeNumber=84, createdTime=2020-02-22, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f351884e941, moduleTitle=诺华的抗血管内皮生长因子（VEGF）单抗Beovu获欧盟批准，用于治疗年龄相关的湿性黄斑变性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f351884e941)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590018, encodeId=97881590018d5, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=艾伯维的JAK抑制剂Rinvoq，获得欧盟批准治疗类风湿性关节炎, objectType=article, longId=185034, objectId=d32d1850343b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d32d1850343b, replyNumber=0, likeNumber=115, createdTime=2019-12-23, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d32d1850343b, moduleTitle=艾伯维的JAK抑制剂Rinvoq，获得欧盟批准治疗类风湿性关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d32d1850343b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590017, encodeId=78d6159001e1a, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=欧盟批准将Evenity（romosozumab）用于治疗绝经后妇女的骨质疏松症, objectType=article, longId=184834, objectId=6c4b184834d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c4b184834d0, replyNumber=0, likeNumber=58, createdTime=2019-12-18, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c4b184834d0, moduleTitle=欧盟批准将Evenity（romosozumab）用于治疗绝经后妇女的骨质疏松症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c4b184834d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590016, encodeId=e9e61590016ba, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=阿斯利康的三合一药物Qtrilmet获得欧盟批准，用于II型糖尿病, objectType=article, longId=183117, objectId=d3c118311e3e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3c118311e3e, replyNumber=0, likeNumber=77, createdTime=2019-11-19, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3c118311e3e, moduleTitle=阿斯利康的三合一药物Qtrilmet获得欧盟批准，用于II型糖尿病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3c118311e3e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590015, encodeId=e9b0159001520, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=欧盟批准Dupixent治疗严重慢性鼻窦炎伴鼻息肉, objectType=article, longId=182189, objectId=dd431821896a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd431821896a, replyNumber=0, likeNumber=64, createdTime=2019-11-01, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd431821896a, moduleTitle=欧盟批准Dupixent治疗严重慢性鼻窦炎伴鼻息肉, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd431821896a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590014, encodeId=29e9159001461, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=GW的大麻类药物Epidyolex获得欧盟批准治疗儿童癫痫, objectType=article, longId=180109, objectId=5d4b18010946, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d4b18010946, replyNumber=0, likeNumber=73, createdTime=2019-09-28, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d4b18010946, moduleTitle=GW的大麻类药物Epidyolex获得欧盟批准治疗儿童癫痫, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d4b18010946)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590013, encodeId=bd71159001323, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=拜耳TRK抑制剂Vitrakvi获得欧盟批准治疗NTRK基因融合的肿瘤患者, objectType=article, longId=180106, objectId=b99c180106aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b99c180106aa, replyNumber=0, likeNumber=56, createdTime=2019-09-28, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b99c180106aa, moduleTitle=拜耳TRK抑制剂Vitrakvi获得欧盟批准治疗NTRK基因融合的肿瘤患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b99c180106aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590012, encodeId=87d71590012ad, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=默沙东“免疫+靶向”组合获欧盟批准一线治疗晚期肾癌, objectType=article, longId=178994, objectId=25591e89942d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25591e89942d, replyNumber=0, likeNumber=90, createdTime=2019-09-07, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25591e89942d, moduleTitle=默沙东“免疫+靶向”组合获欧盟批准一线治疗晚期肾癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25591e89942d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590011, encodeId=8ce31590011c4, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=PD-1单抗Keytruda又一重大突破：与阿西替尼联合获欧盟批准用作晚期肾细胞癌（RCC）的一线治疗, objectType=article, longId=178980, objectId=52fd1e8980a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52fd1e8980a7, replyNumber=0, likeNumber=71, createdTime=2019-09-07, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52fd1e8980a7, moduleTitle=PD-1单抗Keytruda又一重大突破：与阿西替尼联合获欧盟批准用作晚期肾细胞癌（RCC）的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52fd1e8980a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590010, encodeId=fb2215900108d, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=欧盟批准罗氏的PD-L1单抗Tecentriq联合紫杉醇治疗三阴性乳腺癌, objectType=article, longId=178551, objectId=036a1e8551e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=036a1e8551e1, replyNumber=0, likeNumber=80, createdTime=2019-09-03, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=036a1e8551e1, moduleTitle=欧盟批准罗氏的PD-L1单抗Tecentriq联合紫杉醇治疗三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=036a1e8551e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

欧盟批准

2020-05-29

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

欧盟批准Gilead的remdesivir，治疗新冠病毒COVID-19感染

2020-07-05

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

欧盟批准强生的埃博拉病毒疫苗方案

2020-07-03

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

欧盟批准红细胞成熟剂Reblozyl，治疗输血依赖性贫血

2020-07-02

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

欧盟批准维多珠单抗Entyvio上市，用作活动性溃疡性结肠炎或克罗恩病的维持治疗

2020-05-10

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

欧盟批准诺华的IL-17单抗Cosentyx，用于治疗非放射线轴性脊柱关节炎

2020-05-03

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

欧盟批准Shionogi的新型抗生素Fetcroja——用于WHO指定的所有重点革兰氏阴性病原体

2020-05-03

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

欧盟批准武田的TKI抑制剂ALUNBRIG，用作ALK阳性非小细胞肺癌患者的一线治疗药物

2020-04-09

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

欧盟批准2型糖尿病药物GLP-1受体激动剂Rybelsus

2020-04-08

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

辉瑞的美罗华（利妥昔单抗）仿制药Ruxience，获得欧盟批准

2020-04-06

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

Alnylam的第二款RNAi药物Givlaari，获得欧盟批准治疗肝卟啉症

2020-03-07

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

诺华的抗血管内皮生长因子（VEGF）单抗Beovu获欧盟批准，用于治疗年龄相关的湿性黄斑变性

2020-02-22

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

艾伯维的JAK抑制剂Rinvoq，获得欧盟批准治疗类风湿性关节炎

2019-12-23

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

欧盟批准将Evenity（romosozumab）用于治疗绝经后妇女的骨质疏松症

2019-12-18

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

阿斯利康的三合一药物Qtrilmet获得欧盟批准，用于II型糖尿病

2019-11-19

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

欧盟批准Dupixent治疗严重慢性鼻窦炎伴鼻息肉

2019-11-01

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

GW的大麻类药物Epidyolex获得欧盟批准治疗儿童癫痫

2019-09-28

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

拜耳TRK抑制剂Vitrakvi获得欧盟批准治疗NTRK基因融合的肿瘤患者

2019-09-28

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

默沙东“免疫+靶向”组合获欧盟批准一线治疗晚期肾癌

2019-09-07

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

PD-1单抗Keytruda又一重大突破：与阿西替尼联合获欧盟批准用作晚期肾细胞癌（RCC）的一线治疗

2019-09-07

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

欧盟批准罗氏的PD-L1单抗Tecentriq联合紫杉醇治疗三阴性乳腺癌

2019-09-03

科室
- - 订阅+
  - 更多科室
工具
服务